Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)

• Allison S. Limpert,
• Margrith E. Mattmann and
• Nicholas D. P. Cosford

Beilstein J. Org. Chem. 2013, 9, 717–732, doi:10.3762/bjoc.9.82

• Allison S. Limpert Margrith E. Mattmann Nicholas D. P. Cosford Apoptosis and Cell Death Research Program, Sanford-Burnham Medical Research Institute, 10901 N. Torrey Pines Road, La Jolla, California 92037, United States 10.3762/bjoc.9.82 Abstract Amyotrophic lateral sclerosis (ALS) is a fatal

• preclinical characterization of lead compounds that may ultimately provide novel drugs to treat patients suffering from ALS. Keywords: amyotrophic lateral sclerosis (ALS); copper/zinc (Cu-Zn) superoxide dismutase 1 (SOD1); glutamate toxicity; neurodegeneration; oxidative stress; Introduction Amyotrophic

• lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that leads to the dysfunction and death of motor neurons in both the motor cortex and spinal cord. This adult-onset disorder leads to paralysis and eventual death, most commonly by asphyxiation